TY - JOUR T1 - In patients with type 2 diabetes, perindopril-indapamide had similar relative reductions in mortality and cardiac events regardless of AF status JF - Evidence Based Medicine JO - Evid Based Med SP - 177 LP - 177 DO - 10.1136/ebm.14.6.177 VL - 14 IS - 6 A2 - , Y1 - 2009/12/01 UR - http://ebm.bmj.com/content/14/6/177.abstract N2 - Design: post hoc subgroup analysis of a randomised placebo-controlled trial (Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation [ADVANCE] study). ClinicalTrials.gov NCT00145925. Allocation: {concealed}*.† Blinding: blinded (patients and outcome adjudication committee).† Setting: {215 centres in 20 countries in Asia, Australasia, Europe, and North America}.* Patients: 11 140 patients ⩾55 years of age (mean age 66 y, 57% men) who had type 2 diabetes and ⩾1 additional risk factor for cardiovascular events. 847 patients (7.6%) had atrial fibrillation (AF). Patients requiring long-term insulin were excluded. Intervention: fixed combination of perinodopril and indapamide (2 mg/0.625 mg for 3 mo, then 4 mg/1.25 mg) (n = 5569), or placebo (n = 5571). Outcomes: all-cause mortality, cardiovascular (CV) mortality, major cardiac events, major cerebral events, and heart failure. Follow-up period: mean 4.3 years. Patient follow-up: 94% (100% in intention-to-treat analysis). At baseline, … ER -